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The relevance of coagulation factor X protection of adenoviruses
in human sera
MR Duffy1,2, A Doszpoly1,3, G Turner1, SA Nicklin1 and AH Baker1,3
Intravenous delivery of adenoviruses is the optimal route for many gene therapy applications. Once in the blood, coagulation
factor X (FX) binds to the adenovirus capsid and protects the virion from natural antibody and classical complement-mediated
neutralisation in mice. However, to date, no studies have examined the relevance of this FX/viral immune protective mechanism in
human samples. In this study, we assessed the effects of blocking FX on adenovirus type 5 (Ad5) activity in the presence of human
serum. FX prevented human IgM binding directly to the virus. In individual human sera samples (n= 25), approximately half of
those screened inhibited adenovirus transduction only when the Ad5–FX interaction was blocked, demonstrating that FX protected
the virus from neutralising components in a large proportion of human sera. In contrast, the remainder of sera tested had no
inhibitory effects on Ad5 transduction and FX armament was not required for effective gene transfer. In human sera in which FX
had a protective role, Ad5 induced lower levels of complement activation in the presence of FX. We therefore demonstrate for the
first time the importance of Ad–FX protection in human samples and highlight subject variability and species-specific differences as
key considerations for adenoviral gene therapy.
Gene Therapy (2016) 23, 592–596; doi:10.1038/gt.2016.32
INTRODUCTION
Adenovirus (Ad), a double-stranded non-enveloped DNA virus,
is the most frequently used vector in gene therapy clinical trials.
The majority of the research into this large family of viruses,
composed of over 65 different human types, has focused on
species C Ad type 5 (Ad5). Although Ad5 has been shown to be
relatively safe in the thousands of patients treated worldwide to
date, efficacy following intravenous delivery has been limited. This
is largely as a result of the off target host interactions endured by
the virus once it comes into contact with the bloodstream.
Therefore, understanding the behaviour of Ads upon exposure to
blood is pivotal to their successful use in systemic gene therapy
and oncolytic virotherapy applications.
Over the last decade, Ad5 interactions with host circulatory
components has been the subject of extensive investigation.1–3
Several studies have examined the involvement of coagulation
factor X (FX) in determining Ad5 tropism and immunogenicity
in vivo.1,4 Upon contact with blood, the FX Gla domain binds directly
to the adenoviral hexon protein within its hypervariable regions
(HVR5 and HVR7), and facilitates attachment to heparan sulphate
proteoglycan receptors on the cell surface of hepatocytes.1,5,6
Although FX engagement of heparan sulphate proteoglycans has
been proposed to mediate liver gene transfer, a recent study using
mice lacking functional receptors has indicated that hepatocyte
heparan sulphate is not essential for Ad5 liver transduction in mice.7
FX coating of the Ad5 hexon also has a key role in preventing the
virus being recognised by murine natural antibodies, averting
activation and attack by the classical complement system.2 Inclusion
of Ad5-derived HVRs (HVR1–3 and 5–7) into a native non-FX-binding
virus, Ad type 26 (Ad26), sensitised this virus to immune recognition
leading to neutralisation in vitro and in vivo, and directed the virus
to the liver following intravenous delivery in mice.8 Whilst the
aforementioned studies indicate the protective benefits of the FX
interaction for Ad5 infection, other work details the processes by
which FX binding to the virus induces nuclear factor κB-dependant
inflammatory responses following systemic vector administration in
mice and heightens this arm of the host innate immunity.9 Evidently,
FX binding to Ad5 permits important immune-modulatory functions
in mice; however, dramatically less is known about these mechan-
isms in humans. Notably, one recent study demonstrated that in
contrast to murine FX binding to Ad5 and triggering Toll-like
receptor 4-mediated responses on mouse mononuclear cells, human
FX was incapable of activating primary human macrophages,
indicating species-specific events and highlighting the importance
of using human samples for research.10
Major strides have been made in understanding the mediators
of viral biodistribution, cellular receptor binding profiles and
innate immune responses following virus intravenous administra-
tion in vivo. However, the majority of this work has relied heavily
on small animal models, predominantly mice and unfortunately
these studies can only provide limited information in terms of
human translational relevance. The ability of FX to prevent Ad5
neutralisation by natural IgM antibodies and classical complement
in mice has been detailed,2,8 however, no data describing the
significance of this pathway in humans have yet been described.
In the current study, we investigate the importance of FX
protection of Ad vectors from the immune components present
in human sera and highlight the heterogeneous nature of the host
response.
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RESULTS AND DISCUSSION
Human FX interferes with direct binding of purified human IgM
to Ad5
The ability of FX to bind to the Ad5 HVRs, thereby preventing
recognition and attack by murine natural antibodies and comple-
ment in mice has been documented. To study the importance of
this pathway in humans, we began by investigating whether human
IgM (hIgM) bound to Ad5 directly and whether this was influenced
by human FX. We incubated purified hIgM with Alexa Fluor 532-
labelled Ad5 or the FX-binding deficient version Ad5T* (point
mutations within the hexon HVR5 and HVR7(ref. 11)) in the absence or
presence of FX and analysed alterations in virus particle (vp) size
using the NanoSight LM14 (NanoSight, Malvern, UK). Binding of the
free proteins to the fluorescently labelled virus correlates directly
with an increase in size. The NanoSight LM14 and associated NTA
software enables visualisation of nanoparticles in solution, robust
particle-by-particle size measurements and quantification based on
principles of Brownian motion and fluorescence light scattering.12
The lower size detection limit for the NanoSight LM14 is 10 nm, and
whilst a hIgM pentamer is ~ 30 nm, FX is 9 nm and thus not
detectable via this method.12,13 A significant increase in particle size
(~35 nm) was observed in the presence of hIgM, demonstrating a
direct interaction with Ad5 (Figure 1a). Importantly, this interaction
was inhibited when Ad5 was co-incubated with FX, showing the
ability of FX to hinder direct binding of hIgM to Ad5. hIgM also
bound the non-FX-binder Ad5T* (Figure 1a), demonstrating that the
amino acid residues of the virus responsible for interacting with FX
are not required for the hIgM:Ad5 interaction, and as expected, this
was unaffected by FX. FX did not interfere with the binding of
purified hIgG to Ad5 (Figure 1b).
FX shielding of Ad5 and heterogeneity in human samples
Next, we investigated whether hIgM and complement compo-
nents neutralised Ad5 in the absence of FX in whole human sera.
A panel of 25 human sera, previously identified in our lab as
having low levels of pre-existing neutralising hIgG antibodies
(NAbs) to Ad5 (data not shown and some serum samples
identified by Parker et al.14 and renumbered for this study), was
tested for effects on viral transduction in vitro in the absence or
presence of FX. Xbp binds to the FX Gla domain and inhibits its
interaction with the virus.1 Owing to the presence of endogenous
coagulation factors in the human sera, several samples enhanced
Ad5 cellular transduction, an effect significantly reduced by Xbp
(Figures 2a and b). The extent to which FX enhanced Ad5
transduction varied, and this can be the result of differences in the
endogenous concentrations of FX across the human subsets
following blood clotting and serum production and because of
altering levels of NAbs. Of the 25 sera examined, in 14 samples
(56%), Xbp decreased Ad5 transgene expression to levels
significantly below both media controls and serum alone (-Xbp)
in A549 cells (Figure 2a). This demonstrated that without the FX
protective coat, the virus is neutralised by these sera. Importantly,
in the remainder of human samples (44%), Xbp did not decrease
Ad5 transduction compared with controls or incubation with
serum alone, demonstrating that FX was not required for basal
transduction under these conditions. Similar results were observed
using SKOV3 cells, although there were some differences amongst
the cell lines (4 of the 25 sera caused significant neutralisation
compared with media controls and serum alone in only one cell
type) (Figure 2b). Previous studies in mice have shown that the
ability of IgM to inhibit Ad5 gene transfer is directly related to the
antibody titre, with the concentration of murine IgM negatively
correlating with transduction.15 Variations in the levels of an
individual’s natural antibodies may also contribute to differences
shown here amongst our human sera samples.
Species variation in FX–Ad5 protective requirements
FX binding to Ad5 has been documented to protect the virus from
immune neutralisation in mouse, guinea pig and rat sera samples
in vitro.2,8 Therefore, we performed a direct comparison between
mouse sera and representative human sera (pooled sera samples
#17, 22, 24; refer to Figures 2a and b) in which FX did not have
a protective role. In stark contrast to mouse sera, in the absence
of FX, we detected no inhibition by human sera and transduction
was equivalent to the media controls (Figure 2c). Likewise, Ad5T*
transduction was not affected, again in contrast to the mouse sera.
Taken together, these data indicate that FX binding is not
necessary to shield the virus from neutralisation in all human sera.
FX prevents binding of sera components to Ad5 in a subset of
human samples
We next investigated whether FX coating Ad5 was preventing
recognition and direct binding of components in the whole
human sera, to the viral capsid. We divided our serum samples
into two subsets, those in which FX was required to protect the
virus from neutralisation (group A) and those in which FX
protection was not necessary for cellular transduction (Figure 2).
Representative samples from each subset were incubated with
Ad5 or Ad5T* in the absence or presence of Xbp and vp size was
measured using the NanoSight LM14. There was a significant shift
in Ad5 (Figures 3a and b) and Ad5T* (Figure 3c) particle size
following incubation with sera from either group indicative of
interactions with serum composites. These sera represent a
heterogeneous population and some possess low levels of hIgG
Figure 1. Ad5 binds hIgM in a FX-dependent manner. Alexa Fluor 532-labelled Ad5 or Ad5T* vectors (1 × 109 vp) were incubated at room
temperature for 90 min in phosphate-buffered saline (PBS) (10 μl final volume) with physiologically relevant concentrations of (a) hIgM
(100 μgml− 1) or (b) human IgG (10 μgml− 1) in the presence or absence of human FX (5 μg ml− 1), then diluted in 1.5 ml PBS and injected into
the Nanosight. Each result is representative data from a minimum of three separate experiments with ~ 300 completed tracks. Mean± s.e.m.
compared by one-way analysis of variance, Tukey’s post hoc test, *Po0.05 vs matched control or hIgM conditions.
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NAbs capable of binding the virus regardless of FX (Figures 2a
and b). However, only in the presence of group A sera did Xbp
result in a significant increase in Ad5 particle size compared with
incubation with sera alone (Figure 3a). This is indicative of binding
of Ad5 by hIgM and classical complement components in the
absence of FX.
FX influences Ad5 induction of the human classical complement
pathway
We next studied the early signalling effects of hIgM binding to the
virus and the activation of complement pathways. C1q is the
recognition component of the classical complement cascade
which can bind IgG or IgM leading to the formation of C4b2a
convertase, which cleaves C3 to generate C3a.16 C3a is very short
lived and is rapidly cleaved in serum to the more stable product
C3a-desArg, hence C3a-desArg is commonly used as a measure of
complement activation. We observed increased levels of C3a-
desArg in both human sera with high and low pre-existing NAbs
(source of serum samples Parker et al.14) following incubation with
Ad5, and this was further significantly increased by adding Xbp
(Figure 4a, Supplementary Figure 1). The enhanced C3-desArg
signal in the absence of FX vs its presence suggests that the ability
of Ad5 to induce C3-desArg is not solely reliant on FX, however,
FX coating does impact upon the extent of complement-induced
immunogenicity. In FX-depleted plasma, Ad5 caused comparable
levels of C3a-desArg regardless of Xbp (Figure 4b). C3a and
C3a-desArg are common components of classical, lectin and
alternative complement pathways, whilst C1q is selectively
involved in the classical system.17 In human serum devoid of
C1q, no significant increase in C3-desArg was observed with Ad5
in the presence or absence of FX (Figure 4c). These data thereby
indicate C1q-mediated C3 activation (that is, classical comple-
ment) occurs in the presence of FX, but the levels of C3a-desArg
Figure 2. Screening human sera samples to investigate a protective role of FX. (a) A549 and (b) SKOV3 cells: Ad5 (2×1010 vpml−1) were
incubated with media (control) or 25 different human sera − /+40 μgml− 1 Xbp for 30 min at 37 °C. (c) SKOV3 cells: Ad5 or Ad5T* (2 ×1010 vpml−1)
was incubated with media (CON), human or mouse serum − /+ 40 μgml−1 Xbp for 30 min at 37 °C. Representative human serum samples which
did not show a dependence on FX for protection (pooled sera #17, 22, 24) were used in this experiment. Virus suspensions were diluted 200-fold
in serum-free media and 100 μl added to cells for 2 h at 37 °C, then replaced with media with 2% fetal calf serum. Transgene expression was
quantified ~16 h post transduction and relative light units (RLUs) were normalised to mg total protein. Graphs show transduction as a percentage
of control (Ad transduction with media). Media control (*Po0.05) or matched serum–Xbp conditions (#Po0.05) vs serum+Xbp.
Figure 3. Ad binding to human serum components. Alexa Fluor 532-labelled (a+b) Ad5 or (c) Ad5T* (1 × 109 vp) was incubated at room
temperature for 90 min in human sera − /+ 40 μgml− 1 Xbp (25 μl final volume). (a) Sera Group A= sensitive to neutralisation in the absence
of FX (1 × representative of this group, serum sample #5, shown here), (b) Group B=not sensitive to neutralisation in the absence of
FX (1 × representative of this group, serum sample #24 presented here). Samples were diluted in 1.5 ml phosphate-buffered saline and
injected into the Nanosight. Each result is representative data from minimum three separate experiments with ~ 700 completed tracks.
Mean± s.e.m. compared by one-way analysis of variance, Tukey’s post hoc test, *Po0.05 vs matched control or serum–Xbp conditions.
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induction are significantly increased when FX is absent, in the
human sera samples tested. This suggests that the human
pathway is more complex than that observed in mice, in which
no C3a activation occurs in the absence of FX,2,8 and having no
prior exposure to Ad5, the animals contain no pre-existing NAbs.
To conclude, this work shows for the first time that human FX
binding to Ad5 shields the virus against neutralising human
serum. However, we find there is a high level of heterogeneity
amongst individual human samples in their response to Ad5 in the
absence of FX, and viral coating by the coagulation factor is not
always necessary for gene transfer. This is in contrast to mice, in
which FX armament was essential for virus transduction in all
immunocompetent models examined. In addition, we find that
antibody-mediated classical complement effects on Ad5 are more
complex than that previously suggested by small animal model
studies, in which there is no triggering of complement pathways
when FX is present. This work highlights the benefits of using
translationally relevant experimental settings and human samples
to investigate viral and host mechanisms. These data indicate
the importance of screening patient antibody profiles prior to
Ad5-mediated gene therapy, as it will be fundamental in
deciphering the response to treatment.
MATERIALS AND METHODS
Cell lines and viruses
Human embryonic kidney HEK293 cells were cultured in Dulbecco modified
Eagle medium (Invitrogen, Paisley, UK). Human ovarian carcinoma SKOV3
and lung carcinoma A549 cells (National Institutes of Health) were cultured
in RPMI-1640 media (Invitrogen). Medium was supplemented with
2 mM l-glutamine and 10% fetal calf serum. Cells were maintained at
37 °C and 5% CO2. Ad5 and Ad5T* containing mutations within HVR5
(T270P and E271G) and HVR7 (I421G, T423N, E424S, L426Y and E451Q)
were described previously.11
Fluorescent labelling of Ad particles
Ad5 and Ad5T* were fluorescently labelled using an Alexa Fluor 532 protein
labelling kit according to the manufacturer's instructions (Invitrogen).
To remove any free label, the viruses were dialysed overnight using
10 000 molecular weight cutoff slide-a-lyzer cassettes (Perbio Science,
Cramlington, UK) in 100 mM Tris and 50 mM EDTA. Fluorescent dye labelling
efficiency was assessed using the ‘proteins and labels’ function on the
Nanodrop-1000 spectrophotometer (Labtech International Ltd, Uckfield, UK).
NanoSight LM14 particle size tracking
Alexa Fluor 532-labelled Ad5 or Ad5T* vectors (1 × 109 vp) were incubated
at room temperature for 90 min in phosphate-buffered saline (10 μl final
volume) with human serum − /+ 40 μgml− 1 Xbp or with physiologically
relevant concentrations of purified hIgM (100 μgml− 1) or human IgG
(10 μgml− 1) − /+ 5 μgml− 1 human FX. Purified human blood coagulation
FX was purchased from Cambridge Biosciences (Cambridge, UK). Samples
were then diluted in 1.5 ml phosphate-buffered saline, 1 ml of the sample
was injected into the Nanosight LM14 (NanoSight) and fluorescent vp sizes
were tracked. Results show representative data from a minimum of three
separate experiments with ~ 300–700 completed tracks.
Serum neutralisation assays
A549 and SKOV3 cells were plated in a 96-well format (1× 104 cells/well) and
incubated overnight at 37 °C. Sera samples used in experiments were
collected, handled and stored in the same manner. Human sera or murine
sera from C57BL/6 mice were diluted to 80–90% in RPMI-1640 and incubated
with 2×1010 vpml−1 Ad5 or Ad5T* in a final volume of 50 μl. Xbp was
added to test samples at 40 μgml−1 to deplete the FX in the serum prior to
the addition of virus. Controls were Ad alone in serum-free medium. Viruses
were incubated with serum or medium for 30 min at 37 °C. Mixtures
were diluted 200-fold in serum-free medium. Cells were rinsed and 100 μl
of diluted vector (1000 vp per well) was added to triplicate wells for 2 h
at 37 °C. The inoculum was then replaced with medium containing 2% heat-
inactivated fetal bovine serum. After ~ 16 h, cells were rinsed with
phosphate-buffered saline and harvested for determination of luciferase
transgene expression and protein content using the BCA assay. C3a-desArg
ELISAs were performed to ensure an intact complement system in a subset
of sera from all groups.
Figure 4. Effects on human complement activation. Human sera was incubated with Ad (5 × 1010 vpml− 1) in the presence or absence of
40 μgml− 1 Xbp for 90 min at 37 °C. (a) Human sera with high pre-existing neutralising IgG titres (high NAbs) and sera samples with low IgG
titres which exhibited a dependence on FX for protection (low NAbs Group A), (b) FX-depleted human plasma (Quadratech Diagnostics, UK)
and (c) C1q depleted human sera were used. C3a-desArg levels were quantified by ELISA. Graphs show transduction as a percentage of serum
+phosphate-buffered saline (PBS). *Po0.05 vs matched PBS or Ad5.
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C3a-desArg ELISA
Virus (5x1010 vp ml − 1) was incubated with 50 μl of human serum,
FX-depleted plasma (Cambridge Bioscience) or C1q depleted serum
(Quidel, San Diego, CA, USA) − /+40 μg ml − 1 Xbp for 90 min at 37 °C, and
then 10 mM EDTA was added. Samples were frozen at –80 °C until
evaluation in a human C3a-desArg ELISA as previously described.18
Statistical data analysis
Significance was calculated using two sample, two-tailed student’s t-tests
or where described by one-way analysis of variance with Tukey’s post hoc
test. P-values of o0.05 were considered to be significant. Results
presented are representative data from a minimum of three separate
experiments with at least three experimental replicates per group. All error
bars represent s.e.m.
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